Here are the 10-K annual reports from vTv Therapeutics Inc. (VTVT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VTVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTVT filings page.
vTv Therapeutics Inc. files its annual report describing a late-stage biopharmaceutical business focused on orally administered therapies for metabolic and inflammatory diseases, led by cadisegliatin (TTP399) for type 1 diabetes.
Cadisegliatin has FDA Breakthrough Therapy designation and is in the Phase 3 CATT1 trial, which will randomize 150 patients to assess reductions in severe hypoglycemia and improvements in HbA1c. The program recently resumed after the FDA lifted a clinical hold in March 2025.
The company broadened its pipeline with candidates targeting GLP‑1, RAGE, PPAR‑δ and Nrf2/Bach1 pathways and expanded partnered programs, including global rights to PDE4 inhibitor HPP737 licensed to Newsoara. In 2025 it closed an $80 million private placement, plus a $20 million upfront payment from Newsoara, supporting development beyond topline CATT1 data. As of March 10, 2026, vTv had 3,938,654 Class A common shares outstanding.